The Ruling That Shook Surgical Device Markets

In February 2026, a federal jury in the U.S. District Court for the Central District of California returned a verdict that sent shockwaves through the surgical device industry: Medtronic was found to have violated U.S. federal antitrust laws — specifically the Sherman Act, the Clayton Act, and the California Cartwright Act — through anticompetitive bundling and exclusive dealing practices in the market for advanced bipolar vessel sealing devices.

The jury awarded more than $382 million in damages to plaintiff Applied Medical, a rival surgical device manufacturer, after a nearly three-week trial.

Now, Applied Medical has filed a motion for a permanent injunction against Medtronic, seeking to permanently prohibit the anticompetitive sales practices that the jury found unlawful.

What Was Medtronic Accused Of?

At the heart of the case was Medtronic’s market dominance in advanced bipolar devices — surgical instruments that use bipolar electrosurgical energy to cut and seal blood vessels during minimally invasive procedures.

The jury found two primary anticompetitive practices:

  • Anticompetitive bundling — Bundling the sale of bipolar instruments with generators and other surgical devices in ways that penalized hospitals for purchasing competing products.
  • Exclusive dealing arrangements — Using long-term contracts that effectively locked hospitals into single-supplier relationships, preventing adoption of alternative technologies.

The Injunction Motion: What Comes Next

The permanent injunction motion, filed in August 2026, could impose structural constraints including prohibiting bundling arrangements, restricting exclusive supply contracts, and requiring non-discriminatory terms for all hospital purchasing groups.

Why This Matters for Hospitals

  1. Increased supplier choice — Hospitals will have greater freedom to evaluate alternative suppliers based on clinical merit and cost-effectiveness.
  2. Cost reduction — Greater competition typically drives price normalization in surgical device procurement.
  3. Supply chain diversification — Multi-source procurement strategies become more viable when anticompetitive barriers are removed.

What This Means for Certified Alternative Manufacturers

The ruling confirms that the technology underlying advanced bipolar vessel sealing systems is well-established and widely accessible. The barriers were commercial, not technical.

H Group Medical, through its manufacturing subsidiary Hongchuang Medical Devices, has invested over a decade in independently patented bipolar vessel sealing technology. With 3 authorized national invention patents, CE certification, ISO 13485 compliance, and manufacturing facilities exceeding 10,000m², we offer bipolar forceps (Maryland and Blunt tips, 36cm/44cm), monopolar forceps, pincettes, and monopolar hooks — a complete electrosurgical platform at competitive price points.

Looking Ahead

The Medtronic case is part of a broader trend of heightened scrutiny of medical device market practices. In December 2025, TELA Bio filed a similar antitrust complaint against Becton, Dickinson and Company. The FTC recently imposed a record $12 million fine for HSR Act violations in the medical device sector.

For hospitals, the message is clear: diversifying your supplier base is no longer optional — it’s a strategic imperative. For qualified manufacturers with independent IP and international certifications: the market is opening.

For information about our advanced bipolar vessel sealing systems, electrosurgical generators, and OEM partnership opportunities, contact our team.